CSL (CSL) Update

Submitted by Jim Thesiger on 29 May, 2008 - 14:07

CSL (CSL) has a target price of $42.00 from Australian Stockmarket analyst Macquarie Research Equities.

CSL (CSL)Caution on timing of Cervarix US Approval & we update for FX impact

Delays to Cervarix US approval could be protracted:

Overnight, UBS analysts acknowledged that a 2010 USA launch for GlaxoSmithKline’s cervical cancer vaccine "Cervarix" is at risk. UBSe had previously assumed a 2010 launch, a view "more bearish than consensus" which expected US FDA approval in CY09.

Gardasil monopoly till 2010 a boost to royalties payable to CSL:

UBSe forecast Cervarix to rival Gardasil securing c.30% US market share. CSL royalty from Gardasil is superior at c.6.2% vs 1.9% from Cervarix. We now switch near term Cervarix US sales estimates to Gardasil, with upside out to CY10.

Update to spot FX ‘basket’ is negative for CSL:

AUD/USD is trading at c.96 cents, a 4.7% variation to YTD avge; other key currencies in the CSL ‘basket’, EUR & CHF have experienced c.2% variation to YTD. We adjust forecasts for impact at spot rates for balance FY08 and beyond.

Valuation: PT $42 (was $42.43); Neutral Rating (was Buy)

Net impact (post Gardasil & FX changes) to UBSe is -0.8% to FY08 and -2.3% to FY09. Impact to PT is -1%; [PT is set using NAV & DCF at a 10% premium to market multiples], however, with recent strength in CSL trading this results in a Neutral rating. We continue to view CSL as a ‘core portfolio holding’ citing upside risk to Privigen IVIG sales from early plant commissioning along with flu vaccine.

Download our FREE App


Signup for Free
Don't miss out on your free share trading articles.


Free Risk Money Management Calculator for those who sign up!